Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
NCT05446298Phase 2Active, not recruiting
- Sponsor
- OncoC4
- Start
- Dec 2022
- Primary completion
- Aug 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gotistobart in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by OncoC4. Primary endpoints: Objective Response Rate at 24 months and Treatment Related Adverse Events and Immune Related Adverse Events at 24 months. Started Dec 2022; status: active, not recruiting.
02
Drugs
gotistobart
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT05446298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05446298.